Center for Human Genetics Research, Vanderbilt University, Nashville, TN.
Department of Anesthesiology, Vanderbilt University, Nashville, TN.
Am Heart J. 2014 Jan;167(1):101-108.e1. doi: 10.1016/j.ahj.2013.09.016. Epub 2013 Oct 17.
Postoperative atrial fibrillation (PoAF) after cardiac surgery is common and associated with increased morbidity and mortality. Increased sympathetic activation after surgery contributes to PoAF, and β-blockers are the first-line recommendation for its prevention. We examined the hypothesis that common functional genetic variants in the β1-adrenoreceptor, the mediator of cardiac sympathetic activation and drug target of β-blockers, are associated with the risk for PoAF and with the protective effect of β-blockers.
In a prospective cohort study, we studied 947 adult European Americans who underwent cardiac surgery at Vanderbilt University between 1999 and 2005. We genotyped 2 variants in the β1-adrenoreceptor, rs1801253 (Arg389Gly) and rs1801252 (Ser49Gly), and used logistic regression to examine the association between genotypes and PoAF occurring within 14 days after surgery, before and after adjustment for demographic and clinical covariates.
Postoperative atrial fibrillation occurred in 239 patients (25.2%) and was associated with rs1801253 genotype (adjusted P = .008), with Gly389Gly having an odds ratio of 2.63 (95% CI 1.42-4.89) for PoAF compared to the common Arg389Arg (P = .002). In a predefined subgroup analysis, this association appeared to be stronger among patients without β-blocker prophylaxis (adjusted odds ratio 7.00, 95% CI 1.82-26.96, P = .005) compared to patients with β-blocker prophylaxis, among whom the association between rs1801253 genotype and PoAF was not statistically significant (adjusted P = .11).
The Gly389 variant in the β1-adrenoreceptor is associated with PoAF, and this association appears to be modulated by β-blocker therapy. Future studies of the association of other adrenergic pathway genes with PoAF will be of interest.
心脏手术后的房性心律失常(PoAF)很常见,且与发病率和死亡率的增加有关。手术后交感神经激活增加导致 PoAF,β受体阻滞剂是其预防的首选。我们检验了这样一个假设,即心脏交感神经激活的中介和β受体阻滞剂的药物靶点β1-肾上腺素能受体中的常见功能遗传变异与 PoAF 的风险以及β受体阻滞剂的保护作用有关。
在一项前瞻性队列研究中,我们研究了 1999 年至 2005 年间在范德比尔特大学接受心脏手术的 947 名欧洲裔美国成年人。我们对β1-肾上腺素能受体中的 2 个变异基因 rs1801253(Arg389Gly)和 rs1801252(Ser49Gly)进行了基因分型,并使用逻辑回归检验了基因型与术后 14 天内发生的 PoAF 之间的关联,在调整人口统计学和临床协变量之前和之后。
239 例患者(25.2%)发生 PoAF,与 rs1801253 基因型相关(调整后的 P =.008),与常见的 Arg389Arg 相比,Gly389Gly 发生 PoAF 的比值比为 2.63(95%CI 1.42-4.89)(P =.002)。在预先设定的亚组分析中,与接受β受体阻滞剂预防的患者相比(调整后的比值比为 7.00,95%CI 1.82-26.96,P =.005),这种关联在没有β受体阻滞剂预防的患者中似乎更强,在这些患者中,rs1801253 基因型与 PoAF 之间的关联无统计学意义(调整后的 P =.11)。
β1-肾上腺素能受体中的 Gly389 变异与 PoAF 相关,这种关联似乎受到β受体阻滞剂治疗的调节。未来研究其他肾上腺素能途径基因与 PoAF 的关联将是有趣的。